To: Beth Balderston <info@cervicalcanceraction.org>

From: Cervical Cancer Action

From Email: info@cervicalcanceraction.org

Subject: Cervical Cancer Action News Brief

Preheader:



Cervical Cancer Action News Brief | February 2014 News and views of interest to our community

### GAVI announces new HPV vaccine pilot programs

GAVI has approved 10 new countries for HPV vaccine demonstration project support: Benin, Burundi, Cameroon, Cote d'Ivoire, The Gambia, Liberia, Mali, Senegal, Solomon Islands, and Togo.

GAVI HPV demonstration programs help countries "learn by doing" to build capacity and infrastructure that can later expand into nationwide HPV immunization.

For more information, read the GAVI press release.

### Cervical Cancer Action maps updated with new GAVI countries

Visit the Cervical Cancer Action's latest map illustrating <u>global progress in HPV vaccination</u> and a short <u>slide show</u> comparing vaccination in 2010 with 2014.

### Two-dose Cervarix® schedule approved

GlaxoSmithKline announced on December 20, 2013 that the European Commission granted marketing authorization for its cervical cancer vaccine Cervarix® [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] as a two-dose schedule for girls aged 9 to 14. This is the first time a cervical cancer vaccine has been approved as a reduced dosing schedule and signifies potential for lower costs, higher vaccination coverage, and improved cervical cancer protection worldwide.

For more information, read GlaxoSmithKline's press release.

#### Community health promoter course in cervical cancer prevention

Developed by Grounds for Health, <u>We Can Prevent Cervical Cancer</u>; <u>A Course for Community Health Promoters</u> is a resource for any country committed to establishing sustainable cervical cancer prevention programs. The web page includes Spanish and English versions of a community resource book for educational use in the community, PowerPoint presentation, and a community health promoter resource book.

### Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer

This <u>Report to the President of the United States from the President's Cancer Panel</u> provides concrete, targeted, and actionable recommendations—supported by evidence and input from key stakeholders—to address barriers and achieve greater uptake of HPV vaccines by both boys and girls throughout the United States and the world.

#### Updated ICO country and region cervical cancer reports

The Institut Català d'Oncologia (ICO) <u>Information Centre on HPV and Cancer</u> provides updated reports on cervical cancer incidence and other statistics for each country in the world as well as for world regions and the entire globe.

Please note that this is a new web address for the ICO database, as the website has moved, so you may want to update any link you saved in the past.

#### Latest world cancer statistics—GLOBOCAN 2012

The International Agency for Research on Cancer (IARC) has published its latest data on cancer incidence, mortality, and prevalence worldwide. The new version of the IARC online database, GLOBOCAN 2012, provides the most recent estimates for 28 types of cancer in 184 countries and offers a comprehensive overview of the global cancer burden.

## WHO update on HPV vaccine safety

The World Health Organization (WHO) Global Advisory Committee on Vaccine Safety reviewed new HPV vaccine safety data from the United States, Australia, Japan and the manufacturers of Cervarix® (GlaxoSmithKline) and Gardasil® (Merck). From the paper: "...four years after the last review of HPV vaccine safety and with >175 million doses distributed worldwide and more countries offering the vaccine through national immunization programmes, the Committee continues to be reassured by the safety profile of the available products." The discussion of HPV vaccine begins on page 309.

# WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention

These WHO guidelines provide recommendations for strategies for a cervical precancer screen-and-treat program. The quidelines build on previous documents: Use of cryotherapy for cervical intraepithelial neoplasia (published in 2011) and on the new WHO quidelines for treatment of cervical intraepithelial neoplasia 2-3 and glandular adenocarcinoma in situ (forthcoming). The document is intended primarily for policymakers, managers, program officers, and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention at country, regional, and district levels.

# Management of cervical cancer: strategies for limited-resource centres—a quide for radiation oncologists

This publication from the International Atomic Energy Agency is written for radiation oncologists working in centers with limited resources and treating a large number of patients with cervical cancer on a daily basis. The approach and techniques are intended to be simple, feasible, and resource sparing.

### IARC Education and Training Programme website

IARC has launched a new Education and Training Programme website for easy access to their learning and training resources, including many focused on cervical cancer.

# Eighth Annual Stop Cervical, Breast & Prostate Cancer in Africa conference: July 20-22, 2014

The conference will be held in Windhoek, Nambia under the High Patronage of Her Excellency Madame Penehupifo Pohamba, First Lady of Republic of Namibia.

Further information is available on the <u>Stop Cervical Cancer in Africa</u> website.

# **Cervical Cancer Action Governing Council**














#### Secretariat









info@cervicalcanceraction.org | www.cervicalcanceraction.org